Skip to main content
ENDO 2026 Main banner

Thyroid Biology and Disease

ORF49-08 - Subcutaneous MHB018A, a N Ovel Anti- IGF-1R VHH Antibody, for Thyroid Eye Disease (TED): Results from a Phase 1/2 Study in Patients with Active and Chronic TED

Monday, June 15, 2026
3:00 PM - 3:15 PM CT
Location: Room W184ABC

    Senior Author/Primary Investigator(s)

  • ZJ

    Zibing Jin, MD, PhD

    Beijing Tongren Hospital
    Beijing, China (People's Republic)

    • Co-Author(s)

  • JZ

    Jianbo Zhou, MD, PhD

    Beijing Tongren Hospital
    Beijing, China (People's Republic)

  • YS

    Yuhong Shi, MD, PhD

    The 2nd Affiliated Hospital of Chengdu Medical College Nuclear Industry 416 Hospital
    Chengdu, China (People's Republic)

  • XL

    Xiaorong Li, MD, PhD

    Tianjin Medical University Eye Hospital
    Tianjin, China (People's Republic)

  • HJ

    Hongwei Jiang, MD, PhD

    The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, China (People's Republic)

  • YW

    Yihua Wang, MD

    Nanyang First People's Hospital
    Nanyang, China (People's Republic)

  • LT

    Liming Tao, MD, PhD

    The Second Affiliated Hospital of Anhui Medical University
    Hefei, China (People's Republic)

  • XW

    Xiaohong Wu, MD, PhD

    Zhejiang Provincial People's Hospital
    Hangzhou, China (People's Republic)

  • TW

    Tao Wang, MD

    The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, China (People's Republic)

  • YZ

    Yu Zhu, MD, PhD

    The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China (People's Republic)

  • JY

    Jin Yao, MD, PhD

    Nanjing Medical University Eye Hospital
    Nanjing, China (People's Republic)

  • JH

    Ji Hu, MD, PhD

    The Second Affiliated Hospital of Soochow University
    Suzhou, China (People's Republic)

  • YT

    Yanjie Tian, MD

    Peking University Third Hospital
    Beijing, China (People's Republic)

  • JT

    Jia Tan, MD, PhD

    Xiangya Hospital of Central South University
    Changsha, China (People's Republic)

  • WS

    Wencheng Su, MD, PhD

    Deyang People's Hospital
    Deyang, China (People's Republic)

  • SZ

    Shiyu Zhou, PhD

    Minghui Pharmaceutical
    Shanghai, Shanghai, China (People's Republic)

  • JS

    Junwei Shi, MA

    Minghui Pharmaceutical
    Shanghai, China (People's Republic)

    • Oral Abstract Presenter(s)

  • Guoqing Cao, PhD

    CEO
    Minghui Pharmaceutical
    Shanghai, China (People's Republic)

Disclosure(s):
Guoqing Cao, PhD: Minghui Pharmaceutical: Employee (any industry) ()



Introduction:
MHB018A is a novel subcutaneously administered VHH antibody targeting IGF-1R, with potent ligand blocking and functional inhibition of IGF-1 and IGF-2 signaling. Preliminary results from a phase 1/2 study demonstrated encouraging efficacy and a favorable safety profile in patients with active TED (aTED) (ITC 2025). Here, we report updated efficacy and safety results in patients with aTED and chronic TED (cTED).

Methods:
This study comprised a double-blind, randomized phase (A) and an open-label expansion (B). In part A, patients with aTED were randomized (4:1) to receive MHB018A or placebo across three cohorts (10 pts/cohort): Cohort 1, 300 mg every 4 weeks (Q4W); Cohort 2, 600 mg loading dose followed by 300 mg Q4W; and Cohort 3, 450 mg Q4W. In part B, fixed doses of 300 mg or 450 mg Q4W were evaluated in patients with aTED and cTED.

Results:
A total of 71 pts with aTED (Part A: N=30; Part B: N=41) and 33 with cTED (Part B: N=33) were enrolled. Patients with aTED received three doses over 12 weeks. At week 12, proptosis response rates were 56%, 50% and 81% in the 300 mg, 600 mg+300 mg, and 450 mg groups, respectively. Secondary efficacy endpoints consistently favored the 450 mg dose. In patients with cTED, treatment with MHB018A resulted in a proptosis response rate of 76% at week 24, with a mean change from baseline of -2.65 mm. Among patients with diplopia at baseline, 61% achieved a diplopia response. Treatment over 24 weeks was generally well tolerated. Most adverse events were mild and consistent with the known mechanism of IG-1R inhibition. No SAEs or severe hearing-related AEs were reported.

Conclusions:
MHB018A demonstrated clinically meaningful and consistent efficacy in both active and chronic TED, particularly at the 450 mg dose. The favorable tolerability profile and feasibility of subcutaneous administration support continued clinical development of MHB018A as a differentiated IGF-1R-targeted therapy for TED.